Last reviewed · How we verify
NCT05857280
EXOPULSE Mollii Suit, Motor Function & Multiple Sclerosis (EXOSEP 2)
NA trial testing EXOPULSE Mollii Suit Stimulation in Sclerosis, Multiple in 36 participants. Currently enrolling.
31 December 2024
Quick facts
| Lead sponsor | Sheikh Shakhbout Medical City |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 36 |
| Start date | 21 March 2023 |
| Primary completion | 31 December 2024 |
| Estimated completion | 15 April 2025 |
| Sites | 1 location across United Arab Emirates |
Drugs / interventions tested
- EXOPULSE Mollii Suit Stimulation
Conditions studied
- Sclerosis, Multiple — all drugs for Sclerosis, Multiple →
- MS (Multiple Sclerosis) — all drugs for MS (Multiple Sclerosis) →
- Spasticity, Muscle — all drugs for Spasticity, Muscle →
- Spastic — all drugs for Spastic →
Sponsor
Sheikh Shakhbout Medical City
Who can join
Adults 18 to 75, any sex, with Sclerosis, Multiple or MS (Multiple Sclerosis). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to demonstrate the improvement of motor functions related symptoms in patients with MS and spasticity using Exopulse Mollii suit stimulation in Multiple Sclerosis patients with spasticity. The main questions it aims to answer are: * to evaluate the short-term impact of EXOPULSE Mollii suit on balance in adult MS patients suffering from spasticity. * to assess the effects of EXOPULSE Mollii suit on mobility, upper and lower limbs muscle tone, pain, fatigue and quality of life. Participants will participate in: * One baseline visit for inclusion during which the patient will undergo the first session (active or sham) along with evaluations (before and after the session) * One visit after two weeks during which the patient will undergo the second session (active or sham) along with evaluations (before and after the session) * One visit after two weeks of the second stimulation condition; the patients will undergo a third evaluation and receive the EXOPULSE Mollii Suit for the four-week open label phase and will use the suit at home for an active stimulation session every other day for four weeks. * One visit at the end of the open label phase to perform the fourth and last evaluation and return the EXOPULSE Mollii suit. Researchers will compare both Active and Sham groups to demonstrate the improvement of motor functions related symptoms in patients with MS and spasticity using Exopulse Mollii suit.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05857280
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of EXOPULSE Mollii Suit Stimulation
Trials testing the same drug.
- NCT06226376 — Mollii Suit and Fibromyalgia (EXOFIB 2) · NA · completed
- NCT06214975 — EXOPULSE Mollii Suit, Motor Function & Stroke (EXOSTROKE 2) · NA · unknown
- NCT05912595 — EXOPULSE Mollii Suit, Spasticity, Muscular Oxygenation & Multiple Sclerosis (ENNOX 2) · NA · unknown
Other recruiting trials for Sclerosis, Multiple
Currently open trials in the same condition.
- NCT06112639 — The DANCEREX Proof-of-Concept Study for Chronic Neurological Disorders · NA · recruiting
- NCT06428201 — The Efficacy of Tele Rehabilitation- Based Task-Specific Training for Cognitive Function Improvement · NA · active not recruiting
- NCT03900221 — French Registry for Monitoring Pregnancies for Multiple Sclerosis · recruiting
- NCT03600779 — Application of ihMT MRI in Multiple Sclerosis · NA · recruiting
Other Sheikh Shakhbout Medical City trials
Trials by the same sponsor.
- NCT06226376 — Mollii Suit and Fibromyalgia (EXOFIB 2) · NA · completed
- NCT06214975 — EXOPULSE Mollii Suit, Motor Function & Stroke (EXOSTROKE 2) · NA · unknown
- NCT06665893 — Local Proof of Concept of Evira in Abu Dhabi Study · NA · completed
- NCT05912595 — EXOPULSE Mollii Suit, Spasticity, Muscular Oxygenation & Multiple Sclerosis (ENNOX 2) · NA · unknown
- NCT05817994 — Endoscopic Ultrasound Guided Liver Biopsy and Portal Pressure Registry · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05857280 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sheikh Shakhbout Medical City
- Last refreshed: 17 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05857280.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing